Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

March 31, 2025

Conditions

Metastatic Triple-Negative Breast Carcinoma

Interventions

DIAGNOSTIC_TEST

89Zr-atezolizumab PET/CT

All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)

Trial Locations (1)

RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors

lead

Karolinska University Hospital

OTHER